Patent ID: 9701645
Date: 2017-07-11
CPC Classifications: A61K,A61P,C07D

Claim:
1. A orally active composition for treating Parkinson's disease in a subject experiencing same, consisting of an effective amount of a therapeutic composition comprising a diarylmethylpiperazine compound of formula (i) and pharmaceutically acceptable salts of the 4-((alpha-R)-alpha-((2S,5R)-2,5-Dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide compound in an effective amount of about 1 mg/kg to 100 mg/kg to reduce the symptoms of Parkinson's disease and not induce dyskinesia; wherein the diarylmethylpiperazine compound of formula (i) exhibits delta opioid receptor agonist and mu opioid receptor antagonist activity; and an active Parkinson treating agent, wherein the active Parkinson treating agent is levodopa, and wherein the formula (i) compound and the active Parkinson treating agent are combined in a single composition for simultaneous administration and the formula (i) compound reduces any dyskinesia caused by the active Parkinson treating agent.